Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

• Published in: Journal of neuro-oncology 2010-01, Vol.96 (2), p.211-217
• Main Authors: Norden, Andrew D., Raizer, Jeffrey J., Abrey, Lauren E., Lamborn, Kathleen R., Lassman, Andrew B., Chang, Susan M., Yung, W. K. Alfred, Gilbert, Mark R., Fine, Howard A., Mehta, Minesh, DeAngelis, Lisa M., Cloughesy, Timothy F., Robins, H. Ian, Aldape, Kenneth, Dancey, Janet, Prados, Michael D., Lieberman, Frank, Wen, Patrick Y.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Clinical Study - Patient Study; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Magnetic Resonance Imaging; Male; Medicine; Medicine & Public Health; Meningeal Neoplasms - drug therapy; Meningioma - drug therapy; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neurology; Oncology; Protein Kinase Inhibitors - therapeutic use; Quinazolines - therapeutic use; Survival Analysis; Tomography, X-Ray Computed
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-009-9948-7

There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted. The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth. In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients. We have pooled the data and report the results here. Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity. Twenty-five eligible patients were enrolled with median age 57 years (range 29–81) and median Karnofsky performance status (KPS) score 90 (range 60–100). Sixteen patients (64%) received gefitinib and 9 (36%) erlotinib. Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant. For benign tumors, the 6-month progression-free survival (PFS6) was 25%, 12-month PFS (PFS12) 13%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%. For atypical and malignant tumors, PFS6 was 29%, PFS12 18%, OS6 71%, and OS12 65%. The PFS and OS were not significantly different by histology. There were no objective imaging responses, but 8 patients (32%) maintained stable disease. Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma. The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted.